NCT02245867 2025-02-07
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1 Completed
Clinical Trials
8 trialsNCT05521022 2024-04-03
AT02-001
Attralus, Inc.
Phase 1 Recruiting
NCT05201911 2022-09-15
AT03-001
Attralus, Inc.
Phase 1 Completed
NCT04115956 2022-03-28
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Oncopeptides AB
Phase 1 Terminated
NCT02603172 2019-09-23
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Terminated
NCT01777243 2018-07-24
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Completed
NCT01406314 2017-06-09
SAP Depleter Dose Assessment Study in Patients
GlaxoSmithKline
Phase 1 Completed
NCT02953808 2017-01-19
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
GlaxoSmithKline
Phase 1 Completed